Valuation: Zai Lab Limited

Market Cap 2.89B 2.51B 2.37B 2.15B 4.04B 277B 4.05B 28.36B 10.95B 141B 10.84B 10.6B 453B P/E 2026 *
-11.6x
P/E 2027 * -11.6x
Enterprise Value 2.43B 2.11B 2B 1.81B 3.4B 233B 3.41B 23.86B 9.22B 118B 9.12B 8.92B 381B EV / Sales 2026 *
5.56x
EV / Sales 2027 * 4.54x
Free-Float
94.05%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 61 01/04/2014
Director of Finance/CFO 58 07/07/2023
President 62 01/12/2022
Director TitleAgeSince
Chairman 61 01/04/2014
Director/Board Member 83 01/01/2017
Director/Board Member 75 01/01/2017
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 2.89B
-0.58%+0.43%+32.58%-6.20% 78.35B
-2.55%+6.99%+510.30%+44.31% 61.52B
-1.11%+5.08%-11.47%-33.91% 59.78B
+0.14%-1.20%-11.64%+24.21% 46.53B
-0.24%+1.22%+2.36%+154.40% 45.5B
-1.62%-0.76%+51.23%-16.04% 31.84B
-1.81%+3.16%+44.82%+106.78% 25.4B
+0.47%+3.26%+4.94%+144.25% 21.43B
+0.27%+1.96%+59.19%+106.18% 15.77B
Average -0.70%+2.20%+75.81%+58.22% 42.9B
Weighted average by Cap. -0.92%+2.35%+94.88%+39.71%

Financials

2026 *2027 *
Net sales 436M 380M 359M 326M 610M 41.85B 613M 4.29B 1.66B 21.28B 1.64B 1.6B 68.46B 552M 481M 454M 412M 772M 52.94B 776M 5.43B 2.1B 26.92B 2.07B 2.03B 86.6B
Net income -241M -210M -198M -180M -337M -23.07B -338M -2.37B -914M -11.73B -904M -884M -37.75B -211M -184M -173M -158M -295M -20.24B -297M -2.07B -801M -10.29B -793M -775M -33.11B
Net Debt -458M -398M -376M -342M -640M -43.88B -643M -4.5B -1.74B -22.32B -1.72B -1.68B -71.79B -381M -332M -313M -284M -533M -36.51B -535M -3.74B -1.45B -18.57B -1.43B -1.4B -59.73B
Logo Zai Lab Limited
Zai Lab Ltd is a holding company primarily engaged in biopharmaceutical business. The Company is focused on discovering, developing, and commercializing products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. The Company has a series of patented drug candidates from the discovery stage to the late clinical project, including ZEJULA, OPTUNE, QINLOCK, NUZYRA and VYVGART, and others. The Company conducts its businesses within domestic and overseas markets.
Employees
1,784
Trader
Investor
-
Global
-
Quality
ESG MSCI
A
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!